Profile data is unavailable for this security.
About the company
Achilles Therapeutics plc is a United Kingdom-based clinical-stage immuno-oncology biopharmaceutical company. The Company is engaged in developing precision T cell therapies to treat multiple types of solid tumors. Its lead product is a precision tumor-derived T cell therapy targeting clonal cancer neoantigens. Its pipeline includes Chiron: Advanced Non-Small Cell Lung Cancer, Thetis: Melanoma (Monotherapy), Thetis: Melanoma (PD-1 Combination), and other indications. It is focused on advancing cancer therapies through its work in the field of tumor evolution. Its platform enables to identify mutations formed early in the development of a cancer that give rise to antigens that are expressed by all of a patient's cancer cells but are absent from healthy tissue. It refers to this class of solid tumor targets as clonal neoantigens. To identify clonal neoantigens in a patient, it has developed a bioinformatic platform called PELEUS.
- Revenue in USD (TTM)0.00
- Net income in USD-64.43m
- Incorporated2020
- Employees204.00
- LocationAchilles Therapeutics PLC245 Hammersmith Road, Gunnels Wood RoadLONDON W6 8PWUnited KingdomGBR
- Phone+44 208 154 4600
- Websitehttps://www.achillestx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immuneering Corp | 0.00 | -54.18m | 32.32m | 65.00 | -- | 0.4106 | -- | -- | -1.86 | -1.86 | 0.00 | 2.65 | 0.00 | -- | -- | 0.00 | -55.37 | -- | -58.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -16.05m | 32.64m | 4.00 | -- | 5.41 | -- | -- | -1.17 | -1.17 | 0.00 | 0.3807 | 0.00 | -- | -- | 0.00 | -194.65 | -- | -283.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
| Xilio Therapeutics Inc | 0.00 | -70.96m | 33.04m | 73.00 | -- | 1.20 | -- | -- | -2.57 | -2.57 | 0.00 | 0.7474 | 0.00 | -- | -- | 0.00 | -73.11 | -- | -96.98 | -- | -- | -- | -- | -- | -- | -144.29 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
| NKGen Biotech Inc | -100.00bn | -100.00bn | 33.35m | 63.00 | -- | -- | -- | -- | -- | -- | -- | -2.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -100.00 | -- | -210.06 | -- | -- | -- |
| ImmuCell Corp | 21.28m | -3.90m | 33.43m | 74.00 | -- | 1.35 | -- | 1.57 | -0.5030 | -0.5030 | 2.75 | 3.18 | 0.494 | 2.29 | 9.03 | 269,401.50 | -9.05 | -5.16 | -9.97 | -5.53 | 27.55 | 40.04 | -18.31 | -12.64 | 1.00 | -8.14 | 0.3204 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
| LianBio - ADR | 0.00 | -87.98m | 33.50m | 163.00 | -- | 0.1642 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
| Promis Neurosciences Inc | 0.00 | -11.89m | 33.94m | 6.00 | -- | 440.21 | -- | -- | -0.8292 | -0.8292 | 0.00 | 0.0041 | 0.00 | -- | -- | 0.00 | -298.08 | -144.28 | -- | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | 0.00 | -- | -- | -- | 26.85 | -- | -- | -- |
| Achilles Therapeutics PLC (ADR) | 0.00 | -64.43m | 34.22m | 204.00 | -- | 0.2625 | -- | -- | -1.61 | -1.61 | 0.00 | 3.17 | 0.00 | -- | -- | 0.00 | -36.47 | -26.24 | -40.05 | -28.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 2.12 | -- | 33.65 | -- |
| Akari Therapeutics PLC (ADR) | -100.00bn | -100.00bn | 34.31m | 9.00 | -- | -- | -- | -- | -- | -- | -- | -0.4449 | -- | -- | -- | -- | -- | -149.95 | -- | -435.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 43.61 | -- | -- | -- |
| Carmell Corp | 0.00 | -18.29m | 34.77m | 9.00 | -- | -- | -- | -- | -1.58 | -1.49 | 0.00 | -0.0719 | 0.00 | -- | -- | 0.00 | -428.46 | -- | -- | -- | 58.60 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -75.70 | -- | -- | -- |
| Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -40.09m | 34.89m | 15.00 | -- | -- | -- | -- | -1.60 | -1.60 | 0.00 | -0.0482 | 0.00 | -- | -- | 0.00 | -303.75 | -- | -1,499.90 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
| IN8BIO, Inc. | 0.00 | -31.04m | 35.30m | 31.00 | -- | 1.98 | -- | -- | -0.9154 | -0.9154 | 0.00 | 0.4049 | 0.00 | -- | -- | 0.00 | -123.61 | -74.18 | -145.63 | -84.42 | -- | -- | -- | -- | -- | -- | 0.0556 | -- | -- | -- | -5.21 | -- | -4.54 | -- |
| Mink Therapeutics Inc | 0.00 | -20.59m | 36.22m | 31.00 | -- | -- | -- | -- | -0.5964 | -0.5964 | 0.00 | -0.585 | 0.00 | -- | -- | 0.00 | -175.32 | -- | -3,661.37 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.77 | -- | -- | -- |
| Ocean Biomedical Holdings Inc | 0.00 | -45.58m | 36.73m | 9.00 | -- | -- | -- | -- | -1.40 | -1.40 | 0.00 | -0.0642 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -612.50 | -- | -- | -- |
Data as of Jul 08 2024. Currency figures normalised to Achilles Therapeutics PLC's reporting currency: US Dollar USD
50.37%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Syncona Investment Management Ltd.as of 31 Mar 2024 | 11.09m | 26.98% |
| Redmile Group LLCas of 31 Mar 2024 | 1.61m | 3.91% |
| Vestal Point Capital LPas of 31 Mar 2024 | 1.50m | 3.65% |
| Ikarian Capital LLCas of 31 Mar 2024 | 1.44m | 3.51% |
| StemPoint Capital LPas of 31 Mar 2024 | 1.39m | 3.37% |
| Baker Bros. Advisors LPas of 31 Mar 2024 | 1.21m | 2.94% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 1.01m | 2.45% |
| Invus Public Equities Advisors LLCas of 31 Mar 2024 | 755.38k | 1.84% |
| Boothbay Fund Management LLCas of 31 Mar 2024 | 420.48k | 1.02% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 280.93k | 0.68% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
